title: Sanfilippo syndrome: a mini-review.
abstract: Mucopolysaccharidosis type III (MPS III, Sanfilippo syndrome) is an autosomal recessive disorder, caused by a deficiency in one of the four enzymes involved in the lysosomal degradation of the glycosaminoglycan heparan sulfate. Based on the enzyme deficiency, four different subtypes, MPS IIIA, B, C, and D, are recognized. The genes encoding these four enzymes have been characterized and various mutations have been reported. The probable diagnosis of all MPS III subtypes is based on increased concentration of heparan sulfate in the urine. Enzymatic assays in leukocytes and/or fibroblasts confirm the diagnosis and allow for discrimination between the different subtypes of the disease. The clinical course of MPS III can be divided into three phases. In the first phase, which usually starts between 1 and 4 years of age, a developmental delay becomes apparent after an initial normal development during the first 1-2 years of life. The second phase generally starts around 3-4 years and is characterized by severe behavioural problems and progressive mental deterioration ultimately leading to severe dementia. In the third and final stage, behavioural problems slowly disappear, but motor retardation with swallowing difficulties and spasticity emerge. Patients usually die at the end of the second or beginning of the third decade of life, although survival into the fourth decade has been reported. Although currently no effective therapy is yet available for MPS III, several promising developments raise hope that therapeutic interventions, halting the devastating mental and behavioural deterioration, might be feasible in the near future.
authors.affiliation: Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Valstar
authors.forename: G J G
authors.initials: GJ
authors.lastname: Ruijter
authors.forename: O P
authors.initials: OP
authors.lastname: van Diggelen
authors.forename: B J
authors.initials: BJ
authors.lastname: Poorthuis
authors.forename: F A
authors.initials: FA
authors.lastname: Wijburg
mesh_terms: D000118:Acetylglucosaminidase / Q000172:deficiency* / Q000235:genetics; D000123:Acetyltransferases / Q000172:deficiency* / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D002675:Child, Preschool; D020022:Genetic Predisposition to Disease; D006497:Heparan Sulfate / Q000378:metabolism*; D006801:Humans; D006867:Hydrolases / Q000172:deficiency* / Q000235:genetics; D015994:Incidence; D007223:Infant; D008247:Lysosomes / Q000201:enzymology*; D009084:Mucopolysaccharidosis III / Q000175:diagnosis / Q000201:enzymology* / Q000235:genetics / Q000401:mortality / Q000628:therapy; D010641:Phenotype; D011379:Prognosis; D013429:Sulfatases / Q000172:deficiency* / Q000235:genetics; D013997:Time Factors; D055815:Young Adult
chemical_list: D000118:Acetylglucosaminidase; D000123:Acetyltransferases; D006497:Heparan Sulfate; D006867:Hydrolases; D013429:Sulfatases; C514442:HGSNAT protein, human; C018719:N-acetylglucosamine-6-sulfatase; C022708:N-sulfoglucosamine sulfohydrolase; C033079:alpha-N-acetyl-D-glucosaminidase